Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H40O3 |
| Molecular Weight | 412.6047 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 3 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]2CC[C@@H]3[C@]2(C)CCC\C3=C/C=C4/C[C@@H](O)C[C@H](O)C4=C
InChI
InChIKey=LWQQLNNNIPYSNX-UROSTWAQSA-N
InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1
| Molecular Formula | C27H40O3 |
| Molecular Weight | 412.6047 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 3 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/dovonex.html | https://www.ncbi.nlm.nih.gov/pubmed/22879719 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020554s006lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/16880407https://www.ncbi.nlm.nih.gov/pubmed/23777514https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19941115&CC=JP&NR=H06316558A&KC=A
Sources: https://www.drugs.com/dovonex.html | https://www.ncbi.nlm.nih.gov/pubmed/22879719 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020554s006lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/16880407https://www.ncbi.nlm.nih.gov/pubmed/23777514https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19941115&CC=JP&NR=H06316558A&KC=A
7Z-Calcipotriol is an isomeric impurity in vitamin D analog calcipotriol. Synthesis of 7Z-Calcipotriol was disclosed by Japanese company Kuraray Co in a patent application JP 06316558.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1977 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16880407 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Curative | DOVONEX Approved UseCalcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established. Launch Date1993 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
55.9 pg/mL |
0.005 % 1 times / day multiple, topical dose: 0.005 % route of administration: Topical experiment type: MULTIPLE co-administered: BETAMETHASONE DIPROPIONATE |
CALCIPOTRIENE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
24.4 pg/mL |
0.005 % 1 times / day multiple, topical dose: 0.005 % route of administration: Topical experiment type: MULTIPLE co-administered: BETAMETHASONE DIPROPIONATE |
MC1080 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
82.5 pg × h/mL |
0.005 % 1 times / day multiple, topical dose: 0.005 % route of administration: Topical experiment type: MULTIPLE co-administered: BETAMETHASONE DIPROPIONATE |
CALCIPOTRIENE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
59.3 pg × h/mL |
0.005 % 1 times / day multiple, topical dose: 0.005 % route of administration: Topical experiment type: MULTIPLE co-administered: BETAMETHASONE DIPROPIONATE |
MC1080 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model. | 2015-11-13 |
|
| Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. | 2014-03 |
|
| The atopic dermatitis-like symptoms induced by MC903 were alleviated in JNK1 knockout mice. | 2013-12 |
|
| Synthesis and Biological Activity of Diastereomeric and Geometric Analogs of Calcipotriol, PRI-2202 and PRI-2205, Against Human HL-60 Leukemia and MCF-7 Breast Cancer Cells. | 2013-10-31 |
|
| Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. | 2013-06-18 |
|
| Calcipotriol induces autophagy in HeLa cells and keratinocytes. | 2011-04 |
|
| Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment. | 2007-12 |
|
| Effect of topical vitamin D analogue on in vivo contact sensitization. | 2006-10 |
|
| Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. | 2006-08-01 |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005-06 |
|
| Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. | 2005-05 |
|
| Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis. | 2004 |
|
| Nonpsoriatic uses of calcipotriol. | 2002-08-28 |
|
| The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. | 1997-09 |
|
| Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. | 1996-03 |
|
| Cytotoxic effects of 1 alpha,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line. | 1996-02-27 |
|
| Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. | 1995-01 |
|
| Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis. | 1994-12 |
|
| Profile of ligand specificity of the vitamin D binding protein for 1 alpha,25-dihydroxyvitamin D3 and its analogs. | 1994-08 |
|
| Hypercalcaemia during treatment of psoriasis with calcipotriol. | 1994-06 |
|
| Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. | 1994-03 |
|
| Hypercalcaemia associated with calcipotriol (Dovonex) treatment. | 1993-04-03 |
|
| Effects of 1 alpha,25-dihydroxy-vitamin D3 and calcipotriol on organotypic cultures of outer root sheath cells: a potential model to evaluate antipsoriatic drugs. | 1993 |
Sample Use Guides
Apply a thin layer of Dovonex Cream to the affected skin twice daily and rub in gently and completely. The safety and efficacy of Dovonex Cream have been demonstrated in patients treated for eight weeks.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26794805
The immune modulatory effects of betamethasone, calcipotriol and the combination in ex vivo cultures of psoriatic skin and in vitro cultures of primary human cells that recapitulate key cellular activities of psoriatic inflammation were investigated and compared.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:26 GMT 2025
by
admin
on
Mon Mar 31 18:13:26 GMT 2025
|
| Record UNII |
143NQ3779B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000006277
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
||
|
NDF-RT |
N0000175849
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
||
|
WHO-VATC |
QD05AX52
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
||
|
WHO-ATC |
D05AX02
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
||
|
NCI_THESAURUS |
C29708
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
||
|
WHO-ATC |
D05AX52
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
||
|
WHO-VATC |
QD05AX02
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CALCIPOTRIOL
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
143NQ3779B
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
143NQ3779B
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
SUB06046MIG
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
112828-00-9
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
SUPERSEDED | |||
|
Calcipotriene
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
m2914
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID0046648
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
1086141
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
C28900
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
C055085
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
CC-76
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
5288783
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200666
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
112965-21-6
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
SUB22029
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
6376
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
DB02300
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
2778
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
29365
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000085642
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
465
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY | |||
|
50749
Created by
admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
Calcipotriene impurity G and calcipotriene impurity H not more than 0.25%
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Calcipotriene impurity G and calcipotriene impurity H not more than 0.25%
CHROMATOGRAPHIC PURITY (TLC)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |